17 November 2026 | Tuesday | Report
Reimbursement and vaccine funding decisions across Asia-Pacific now turn on those subjects: epidemiology and health policy. Postgraduate study in public health addresses the shortfall, and the shorter routes can be completed while staying in post.
Japan is the clearest case. Since April 2019, the Central Social Insurance Medical Council (Chuikyo) has used cost-effectiveness evaluation to adjust prices after reimbursement, with assessment support from the Center for Outcomes Research and Economic Evaluation for Health (C2H) at the National Institute of Public Health. The line sits at an incremental cost-effectiveness ratio of ¥5 million per quality-adjusted life year. Below it, a product keeps its price. Above it, the adjustment rises in steps.
China does it differently. The National Healthcare Security Administration, set up in 2018, updates the National Reimbursement Drug List through annual negotiations where price and evidence of value get argued together.
Either way, the sums rest on epidemiology. A cost-effectiveness ratio depends on how many patients have the condition and what baseline risk applies locally. A health economist may build the model. The market access lead still has to defend it before a payer, and that means knowing where the numbers came from and what happens when a Western registry figure is swapped for a local one.
Randomised trials rarely answer every question a payer in the region asks, especially when Asian patients were thinly represented in registration studies or a single-arm trial supported approval. So companies turn to registries and claims databases, which have known weaknesses. Confounding by indication is one: sicker patients get channelled towards the newer drug. Immortal time bias is subtler. Patients must survive long enough to receive treatment, and that waiting period gets counted in the treated group's favour. A reviewer will look for both.
Regional guidance has followed. The REALISE working group, led from the National University of Singapore's Saw Swee Hock School of Public Health and Thailand's Health Intervention and Technology Assessment Program, brings together experts from eleven Asian health systems. Its guidance on using real-world data in reimbursement decisions is non-binding, but it puts observational study design into the daily work of market access teams.
Staff who want that grounding without stepping away from work can look at Victoria University's online postgraduate certificate in public health, which includes a unit on epidemiology and biostatistics. The unit covers how observational data is collected and analysed, and students learn to evaluate existing studies. A dossier review tests that skill.
Vaccine decisions put the same skills under more public scrutiny, because they cover a whole population rather than a defined patient group.
Take respiratory syncytial virus in Australia. The maternal vaccine Abrysvo joined the National Immunisation Program in February 2025. The monoclonal antibody nirsevimab did not, and was left to state and territory programmes with differing eligibility criteria. Then came the legal change. An April 2026 amendment widened the definition of a vaccine to include passive immunisation, and the Pharmaceutical Benefits Advisory Committee (PBAC) took up nirsevimab at an intracycle meeting that September. Its outcomes, published in October, recommend adding the antibody to the national programme and cite infants the maternal vaccine can miss, such as those born within two weeks of their mother's dose.
The coverage gaps in that reasoning are epidemiology. The legislative change that allowed it is health policy, and a team tracking only the clinical file could have missed it. Nor does a recommendation fund anything. That decision sits with the federal government.
Japan shows the cost when public confidence fails. In June 2013 the Ministry of Health, Labour and Welfare suspended its proactive recommendation for human papillomavirus vaccination after reports of adverse events. The vaccine stayed on the routine schedule. It made little difference. Cohort estimates put first-dose uptake among newly eligible girls above 70% before the suspension and at 0.3% after it, and the recommendation did not return until April 2022.
Interpreting adverse event reports against background rates is an epidemiological task. Explaining the result to a worried public is a health policy one. Conventional commercial or regulatory training covers neither well.
A brand manager will not come out of a graduate certificate as a pharmacoepidemiologist. Or as a health economist. Companies that run their own real-world studies or cost-effectiveness models still need specialists, and for those roles a master's degree or dedicated health economics training is the better fit.
Who is the shorter course for, then? A market access or medical affairs manager who needs to challenge a weak comparison and follow a committee's reasoning.
Employers can test for this cheaply. Take a recent PBAC public summary document in the team's therapy area and ask a manager to explain why the committee discounted part of the submitted evidence. A manager who can do that unaided may need no further training. If nobody on the team can, you know where to start.
Some of the content will sit further from a commercial role. Health promotion is the obvious example, although it does help in understanding how governments plan programmes. Staff based outside Australia should also confirm enrolment and fee terms with any Australian provider before committing, because loans and subsidised places there are tied to government eligibility rules.
Most Read
Bio Jobs
News